<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918424</url>
  </required_header>
  <id_info>
    <org_study_id>804P303</org_study_id>
    <nct_id>NCT00918424</nct_id>
  </id_info>
  <brief_title>Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects</brief_title>
  <official_title>Long Term Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      Follow-on study to continue evaluation of the safety of OXC XR as adjunctive therapy in&#xD;
      pediatric epilepsy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric patients with partial onset epilepsy enrolled in a pharmacokinetic study of OXC XR&#xD;
      were allowed to continue treatment with the investigational drug in this extensión study. The&#xD;
      primary interest was in assessing the safety of treatment with OXC XR over a period of&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <start_date>June 2009</start_date>
  <study_type>Expanded Access</study_type>
  <condition>Epilepsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxcarbazepine Extended Release</intervention_name>
    <description>OXC XR is a once-daily formulation of oxcarbazepine and is given at the same dosage levels.</description>
    <other_name>Oxtellar XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide written informed assent (IAF), as appropriate, with written informed&#xD;
             permission (and informed consent (ICF) where required by regional laws or regulations)&#xD;
             from the parent or legally-authorized representative (LAR).&#xD;
&#xD;
          2. Was eligible for and completed the 804P107 study.&#xD;
&#xD;
          3. Weight within the 25 - 75 % weight-for-age percentiles based on the National Center&#xD;
             for Health Statistics Growth Charts, and not less than 15.0kg, when entering the&#xD;
             804P107 study.&#xD;
&#xD;
          4. Able and willing to swallow whole tablets.&#xD;
&#xD;
          5. Females of childbearing potential (FOCP) should either be sexually inactive&#xD;
             (abstinent) for 14 days prior to entering the 804P107 804P107, throughout this study,&#xD;
             and for four days following the last dose; or, if sexually active, will be using one&#xD;
             of the following acceptable birth control methods:&#xD;
&#xD;
               1. Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral&#xD;
                  oophorectomy) six months minimum;&#xD;
&#xD;
               2. Intrauterine device in place for at least three months;&#xD;
&#xD;
               3. Barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to&#xD;
                  the first dose of the 804P107 study, throughout the study, and for four days&#xD;
                  following the last dose;&#xD;
&#xD;
               4. Surgical sterilization of the partner (vasectomy for six months minimum);&#xD;
&#xD;
               5. Hormonal contraceptives in addition to a barrier method (condom, diaphragm) with&#xD;
                  spermicide for at least 14 days prior to the first dose of the 804P107 study,&#xD;
                  throughout the study, and for four days following the last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Meets criteria for history of major depressive or manic episode, according to&#xD;
             Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision.&#xD;
&#xD;
          2. Any history of suicide intent and/or attempt.&#xD;
&#xD;
          3. History or presence of clinically significant, chronic medical condition, especially&#xD;
             those contraindicating antiseizure medication, (e.g., any neurological,&#xD;
             gastrointestinal, endocrine, cardiovascular, pulmonary, hematological, immunologic,&#xD;
             renal, hepatic or metabolic disease) that may affect the safety of the subject in the&#xD;
             opinion of the Investigator.&#xD;
&#xD;
          4. Use of felbamate with less than 18 months of continuous exposure prior to screening&#xD;
             for the 804P107 study and continuous use throughout this study.&#xD;
&#xD;
          5. Frequent need of rescue benzodiazepines (more than once in a 28 day period).&#xD;
&#xD;
          6. Use of diuretics or other sodium-lowering medications.&#xD;
&#xD;
          7. History or presence of clinically significant laboratory, electrocardiogram (ECG), or&#xD;
             vital sign abnormalities that may affect the safety of the subject, in the opinion of&#xD;
             the Investigator at the end of study visit for the 804P107 study.&#xD;
&#xD;
          8. Presence of potential hepatic function impairment as shown by, but not limited to,&#xD;
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3 times the upper&#xD;
             limit of normal (ULN), or total bilirubin &gt;1.5 times ULN, according to the lab results&#xD;
             of the 804P107 study.&#xD;
&#xD;
          9. Presence of suspected impairment of renal function defined by serum creatinine ≥1.5&#xD;
             times ULN, according to the lab results of the 804P107 study.&#xD;
&#xD;
         10. Females who are pregnant or lactating.&#xD;
&#xD;
         11. Previous known hypersensitivity to OXC or other related drugs, such as carbamazepine.&#xD;
&#xD;
         12. Any reason which, in the opinion of the Investigator, would prevent the subject from&#xD;
             participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxcarbazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

